ASX News

Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer

Melbourne (Australia) and Nantes (France) – 16th Dec 2019. Telix Pharmaceuticals and French company ATONCO S.A.S announce they have entered into a Licence and Development Agreement

Telix Pharmaceuticals Limited and French company ATONCO S.A.S are pleased to announce they have entered into a Licence and Development Agreement that will enable ATONCO to investigate the use of Telix’s Molecularly Targeted Radiation (MTR) intellectual property for the treatment of non-muscle invasive bladder cancer that is resistant to standard therapies.

To read the full media release please click here.